Latest News

Displaying articles 37 - 42 of 826 in total

Notice of 2017 Annual General Meeting

Thumbnail

18th Annual General Meeting (57th AGM since MS Ireland’s foundation) Dear Member, In an effort to reduce costs and with the passing of our Constitution last September, we are now able to send AGM notices to you by email. However, we need your consent that you will access the accompanying ...

Published by MS Ireland on Thursday April 13 2017 10:36 AM

View Article

Call Out for New Board Members

Thumbnail

Apply now to become a Director  We are currently seeking candidates to go on to our panel of potential Board members. Members, branches, council, the board and staff may propose candidates. All nominations must be proposed and seconded by members. The nominating committee review the applica...

Published by MS Ireland on Thursday April 13 2017 10:00 AM

View Article

Hope

Thumbnail

‘This week Helen Farrell examines how the years of living with MS have made an impact on her hopes for the future’ This week a brand new MS medication, Ocrevus (ocrelizumab), was approved by the Federal Drugs Authority (FDA)in the United States for both primary progressive (PPMS) and...

Published by Helen Farrell on Thursday April 06 2017 11:00 AM

View Article

Advocacy Strategy

Thumbnail

MS Ireland’s Strategic Plan 2015-2019 Advocacy is one of five Strategic Priorities in MS Ireland’s Strategic Plan 2015-2019. We believe it is crucial that a collective voice for people affected by MS is heard in order to influence national policy decisions and ensure the interests of...

Published by MS Ireland on Tuesday April 04 2017 08:36 AM

View Article

Daclizumab

Thumbnail

New treatment option available to help Irish Patients in fight against Multiple Sclerosis (MS) Daclizumab has a ‘double-action’ approach – offering a new once-monthly treatment option for people living with MS in Ireland. A new once-monthly treatment for relapsing multiple scl...

Published by Biogen on Monday April 03 2017 12:24 PM

View Article

Ocrelizumab

Thumbnail

First treatment licensed for primary progressive MS in the US Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US. It is the first licensed treatment for people with primary progressive MS. The decision was made by the US Food and Drug Administrat...

Published by MS Ireland on Thursday March 30 2017 03:09 PM

View Article


Latest News

More news

What's hot

Skydive_signpost_1

Skydive for MS in 2017

Can you imagine the adrenalin rush after jumping out of a plane at 10,000FT? Well wonder no more! Sign up to our Skydive for MS in September 2017 and find out for yourself!

Find out more

Events Calendar

» Our next Event

27 June 2017: Ongoing Group physiotherapist led exercise classes for people with MS

View all events

eNEWS SIGNUP

If you'd like to receive e-news updates from The Society please enter your email address below. If you want to know more about how we manage personal data then please see our privacy policy.

My local MSI

Map of MS Ireland's service areas South Mid West West Midlands South East North East North West North Dublin City and Fingal South West Dublin and Kildare South East Dublin and Wicklow